Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CLLS | US
0.69
19.22%
Healthcare
Biotechnology
30/06/2024
13/04/2026
4.28
4.41
4.55
4.03
Cellectis S.A. a clinical stage biotechnological company develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19 an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris France.
View LessPositive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
98.1%1 month
85.8%3 months
73.3%6 months
81.2%-
-
1.29
0.74
0.27
-3.90
1.32
-
-77.39M
447.55M
447.55M
-
-181.11
-
374.90
-64.37
20.35
0.44
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.56
Range1M
1.56
Range3M
1.56
Rel. volume
6.68
Price X volume
1.36M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kamada Ltd | KMDA | Biotechnology | 8.44 | 485.13M | -0.59% | 20.15 | 3.41% |
| Fulcrum Therapeutics Inc | FULC | Biotechnology | 7.73 | 482.36M | 2.38% | n/a | 3.53% |
| Aviragen Therapeutics Inc | AVIR | Biotechnology | 5.71 | 482.05M | 0.71% | n/a | 0.43% |
| XOMA Corporation | XOMA | Biotechnology | 38.65 | 452.38M | 5.20% | n/a | 121.93% |
| Esperion Therapeutics Inc | ESPR | Biotechnology | 2.22 | 450.57M | 2.30% | n/a | -161.71% |
| REGENXBIO Inc | RGNX | Biotechnology | 9.04 | 446.79M | 2.73% | n/a | 45.57% |
| Adlai Nortye Ltd. | ANL | Biotechnology | 12.06 | 445.02M | 8.06% | n/a | 72.87% |
| Emergent BioSolutions Inc | EBS | Biotechnology | 8.24 | 435.95M | 3.52% | n/a | 226.97% |
| PureTech Health plc | PRTC | Biotechnology | 17.805 | 426.29M | 7.91% | n/a | 39.49% |
| CorMedix Inc | CRMD | Biotechnology | 7.32 | 422.81M | 1.10% | n/a | 1.29% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 21.87 | 363.20M | 1.63% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.08 | 319.51M | -2.88% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 2.97 | 284.52M | -1.33% | n/a | 174.23% |
| Urban One Inc | UONEK | Broadcasting - Radio | 5 | 265.04M | -4.40% | n/a | 268.43% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.57 | 262.81M | 1.47% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 17.89 | 199.61M | 2.64% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.99 | 160.41M | -0.70% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.69 | 99.62M | -0.67% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 5.85 | 95.29M | 4.09% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.6936 | 73.22M | -0.73% | 14.48 | 7.10% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.90 | - | Cheaper |
| Ent. to Revenue | 1.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.29 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 73.34 | - | Par |
| Debt to Equity | 0.74 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 447.55M | - | Emerging |